Myron Kaplan joined the Board of CorMedix in May 2016. Mr. Kaplan is a founding partner of Kleinberg, Kaplan, Wolff & Cohen, P.C., where he has practiced corporate and securities law for more than forty years. Among other responsibilities at the firm, Mr. Kaplan represents hedge funds and other companies in a broad spectrum of industries and works on financings, mergers and acquisitions, governance and compensation issues, distribution and license agreements and joint ventures. In 2012, Mr. Kaplan became a trustee of the Lehman Brothers Plan Holding Trust. He has served as a Director of a number of public companies and nonprofit organizations. Previously, he served as a member of the board of directors of SAirGroup Finance (USA) Inc., a subsidiary of SAirGroup that had publicly issued debt securities, Trans World Airlines, Inc. and Kitty Hawk, Inc. Mr. Kaplan graduated from Columbia College and holds a Juris Doctor from Harvard Law School.
Alan W. Dunton, M.D. joined the CorMedix board in February 2019. He has devoted his 35-year career to the discovery and development of new drug products. Most recently, he was Senior Vice President of Research and Development at Purdue Pharmaceuticals L.P., based in Stamford, CT. During his career, Dr. Dunton has built a successful consulting company, Danerius LLC. He was also chief executive officer of two biotech companies, and was President and Managing Director of the Janssen Research Foundation, the R&D and regulatory arm of the pharmaceutical division of Johnson & Johnson. His earlier experience includes positions at Roche, Syntex, and Novartis. Dr. Dunton holds an M.D. from New York University School of Medicine, where he completed a residency in internal medicine. He was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center. In 1987, he was awarded The Nellie Westerman Prize from the American Federation for Clinical Research for his work in medical ethics. Dr. Dunton currently serves on the boards of two public companies, Palatin Technologies, Inc. and Oragenics, Inc. He is also a member of the board of Cytogel Pharma LLC, a private bio-pharmaceutical development company focused on acquiring promising early-stage programs.
Greg Duncan joined the CorMedix board in November 2020. Greg currently serves as the Chairman and CEO of Virios Therapeutics, a clinical-stage biopharmaceutical company developing and commercializing innovative antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM). Prior to joining his current company in 2020, Greg served as President and CEO of Celtaxsys, a privately held biotechnology company focused on cystic fibrosis and other rare, inflammatory diseases. Greg spent the majority of his career in senior leadership roles in commercial stage pharmaceutical companies, including UCB, where his roles included serving as President of its North America business. In addition to acting on the executive committee and guiding the strategic direction for the company’s specialty biopharma business, Greg was responsible for managing a multi-billion dollar global business and overseeing the launches of multiple new products. Prior to his roles with UCB, Greg spent approximately 18 years at Pfizer where he gained significant experience across sales and marketing functions including serving as SVP of US Marketing and later as President of Pfizer’s Latin America business. Greg received his undergraduate degree from the State University of New York, Albany, and earned an MBA degree from Emory University.
Janet Dillione joined the Board of CorMedix in August 2015. Since November 2020, Janet has served as the Chief Executive Officer of Contact America, a nationally recognized leader in comprehensive telehealth and remote patient monitoring solutions. Prior to joining Contact America, she served as Chief Executive Officer of Bernoulli Enterprise, Inc since May 2014, a real-time connected healthcare information technology company. Previously, she was Executive Vice President and General Manager of the Healthcare Division at Nuance Communications, Inc., a leading provider of voice and language solutions for businesses and consumers around the world. From June 2000 to April 2010, Ms. Dillione held several senior level management positions at Siemens Medical Solutions, a global leader in medical imaging, laboratory diagnostics, and healthcare information technology, including President and CEO of the global healthcare IT division. Ms. Dillione has more than 25 years of experience leading global teams in the development and delivery of healthcare technology and services. In that time, she has acquired both financial expertise and significant senior management experience as a chief operating officer and executive officer that will allow her to be a valued addition to the company’s Board of Directors.
Mr. Joe Todisco is Chief Executive Officer of CorMedix and a member of the Board of Directors. Prior to joining CorMedix, he spent eleven years in various roles at Amneal Pharmaceuticals, most recently as Chief Commercial Officer of Amneal Specialty, as well as Senior Vice President Corporate Development & International Operations. He was also co-founder and formerly chief executive of Gemini Laboratories LLC, a specialty pharmaceutical company that was subsequently acquired by Amneal. Prior to joining Amneal, Joe spent more than five years leading Ranbaxy Pharmaceutical’s North American Commercial Strategy and Business Development, and prior to Ranbaxy, held various leadership roles with Par Pharmaceuticals. Joe holds a bachelor’s degree in Economics from Georgetown University and an M.B.A. from Fordham Graduate School of Business.
Paulo Costa joined the CorMedix board in September 2020. Mr. Costa currently serves as Chairman of the Board of MacroGenics, a public late stage biopharma company focused on oncology. In addition, he served as Chairman of Amylin Pharmaceuticals, a commercial stage biopharma company, until its sale to Bristol-Myers Squibb and AstraZeneca in a $7 billion transaction in 2012. Prior to his retirement, Mr. Costa served in senior leadership roles at Novartis, including President and CEO of Novartis US Corporation from 2005 to 2008 and President and CEO of Novartis Pharmaceuticals US and Head of Americas from 1999 to 2005. Prior to joining Novartis, Mr. Costa spent 30 years at Johnson & Johnson including as President of Janssen Pharmaceuticals, Inc. During the course of his career, he helped launch and grow a broad range of primary and specialty care products and has built and shaped pharmaceutical sales forces globally. Mr. Costa received his undergraduate degree from São Paulo School of Business Administration and earned a masters degree in business administration from Harvard Business School.
Mr. Lefkowitz is the Founder of Wade Capital Corporation a financial advisory services company focused on small and middle markets and has been its President since June 1990. Mr. Lefkowitz has also served as a director of both publicly traded and privately held companies. He has been a director of AIS, RE, a privately held reinsurance company since 2001. Mr. Lefkowitz was a director of Franklin Credit Management Corporation, formerly known as Franklin Credit Holding Corporation, a public specialty consumer finance company from 1996 through 2015, and a director and chairman of the board of MedConx, Inc., a privately held medical devices connector company from 2007 through 2015. Mr. Lefkowitz received his A.B. from Dartmouth College in 1977 and his M.B.A. from Columbia University in 1985. Mr. Lefkowitz returns to the board of CorMedix where, as a director from August 2011 to June 2016, he brought his extensive experience in financing micro-cap biotech companies and helped the company successfully complete multiple capital raises. He served as the interim Chief Financial Officer of CorMedix from August 15, 2013 to July 20, 2014.
